bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 3697: Development of a focused non-hydrolyzable phosphopeptide library based on a high affinity SHP2 substrate
Authors: Lawrence Harshani R. , Luo Yunting , Gunawan Steven , Becker Andreas , Ren Yuan , Schonbrunn Ernst , Wu Jie , Lawrence Nicholas J. 
Published: August 2015

Abstract
The Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2), a widely expressed cytoplasmic tyrosine phosphatase with two src-homology 2 (SH2) domains, has received much attention in the signal transduction field. SHP2 is a transducer of growth factor, cytokine, integrin, and hormone signaling pathways that regulate processes such as cell proliferation, differentiation, adhesion, migration, and apoptosis and plays a pivotal role in growth factor and cytokine signaling. Gain-of-function SHP2 mutations are associated with several types of leukemias, and solid tumors; this makes SHP2 is an attractive target for cancer therapy Several small molecules have been developed for inhibition of this important phosphatase, which serve as chemical tools to probe the role of SHP2 in disease and lead compounds for optimization. Nevertheless it is challenging to improve these lead compounds with better potency, selectivity and cell permeability. To gain structural insights for development of potent and selective SHP2 inhibitors, we synthesized a non-hydrolyzable phosphotyrosine peptide mimetic based on reported SHP2 substrate peptide sequence (10-mer). The non-hydrolyzable phosphopeptide, containing the phosphotyrosyl surrogate difluoromethylphosphonate, was synthesized using solid phase peptide synthesis methods from the known building block N-FMOCF2Pmp and we improved the coupling reaction conditions to generate a peptide library of difluoromethylphosphonate to understand the SHP2 affinity. We will present the synthesis of the peptide library, analysis of SHP2 phosphatase inhibition, and the binding mode (X-ray crystal structure) of the phosphopeptide mimic to SHP2.
Citation Format: Harshani R. Lawrence, Yunting Luo, Steven Gunawan, Andreas Becker, Yuan Ren, Ernst Schonbrunn, Jie Wu, Nicholas J. Lawrence. Development of a focused non-hydrolyzable phosphopeptide library based on a high affinity SHP2 substrate. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3697. doi:10.1158/1538-7445.AM2015-3697
Abstract 3698: The landscape of published cancer meta-analyses: a descriptive look from 2008-2013
Authors: Qadir Ximena V. , Clyne Mindy , Lam Tram K. , Khoury Muin J. , Schully Sheri D. 
Published: August 2015

Abstract
Cancer epidemiology has undergone rapid growth in the past two decades. This rapid expansion of scientific literature in cancer epidemiology has required scientists to increasingly look towards meta-analyses to help navigate the “sea of literature”. Knowledge integration has facilitated the movement of translation of scientific findings into clinical applications, evidence-based recommendations and population health impact. Performing meta-analysis has allowed scientists to filter through large datasets and translate these scientific or clinical findings effectively. To our knowledge, there has never been a systematic attempt to compile meta-analyses in cancer. Here, we describe the landscape of cancer meta-analyses including publication production stratified by year, cancer outcome measures, study design, cancer type, journal and country leaders in the field.
To ascertain human cancer meta-analytical studies published in the scientific literature during the years 2008 through 2013, we searched PubMed using a text query and the Human Genome Epidemiology (HuGE) Navigator. Two reviewers read through abstracts to determine whether the articles met inclusion criteria. Articles were included if there was a meta-analytical analysis of a human cancer measurement and met one of the following outcome criteria: 1) risk of disease, 2) diagnostic measure, 3) prognostic measure, 4) treatment of disease, including long-term survival and/or adverse events and 5) screening for disease. Coding of articles involved extracting information from the Medline version of each PubMed article reference (i.e. Journal title, year of publication, first author location and cancer-site mesh terms), and by manually reviewing abstracts for classification on the human cancer outcome measurement and other manually coded information.
A total of 4,007 cancer meta-analyses were captured by PubMed from 2008 to 2013. Our systematic review of cancer meta-analyses publications indicates a rapid growth of cancer meta-analyses worldwide with 20% production in the past 6-year time period. Furthermore, PLoS One and Asian Pacific Journal of Cancer Prevention were recorded as the top two publishers in the research field. Genomic, clinical and modifiable cancer risk factors were captured as the top leading cancer meta-analyses studies. Observational studies were captured as the leading meta-analyses study design. In the past five years there was an increased wide distribution of meta-analyses on all cancer types.
Citation Format: Ximena V. Qadir, Mindy Clyne, Tram K. Lam, Muin J. Khoury, Sheri D. Schully. The landscape of published cancer meta-analyses: a descriptive look from 2008-2013. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3698. doi:10.1158/1538-7445.AM2015-3698
Abstract 3701: Health disparity characteristics on growth patterns of breast cancer mortality trends among the US Counties, 1989-2010
Authors: Yoo Wonsuk , Rust George , Zhang Shun , Lillard James 
Published: August 2015

Abstract
Background: Group-based trajectory models are increasingly being applied to address questions related to the development of cancer mortalities over time and, more recently, there is a need to move away from the interpretation of trajectory groups as distinct entities. In this study, we aim to identify trajectory-patterns which have distinct epidemiologic disparity among US counties, and to assess whether health disparities in the socioeconomic characteristics are associated with a greater women health burden in breast cancer.
Methods: Cases of breast cancer diagnosed between 1989 and 2010 were selected from Center for Disease Control's WONDER Online Databases using International Classification of Diseases for Malignant neoplasm of breast (ICD 10 - C50). Age-adjusted mortality rates of breast cancer between 1989 and 2010 were calculated by counties as well as race (African American and White). Growth patterns were identified using Growth Mixture Modeling (GMM) method and disparity characteristics including socioeconomic attributes were investigated through National Cancer Institute's Surveillance Epidemiology and End Results (SEER) County Attributes Dataset.
Results: We identified the following three growth sub-patterns in the trajectories of breast cancer mortality rates between 1989 and 2010 among US counties: (1) a majority (61%) following a gradual decreasing trajectories, (2) a non-decreasing trajectories (31%), and the remainder following a trajectory with relatively rapid decreasing (7%). We compared disparity characteristics of education level, median household income, poverty percentage, percentages of older ages (65+) and younger ages (&lt;18), and rural-urban continuum among above three sub-patterns.
Conclusions: There is heterogeneity of the socioeconomic characteristics that are highly associated with growth patterns in trajectories of breast cancer mortality rates. Growth mixture models are an effective tool to be able to capture health disparities in heterogeneity among counties in the trajectory of breast cancer mortality.
Note: This abstract was not presented at the meeting.
Citation Format: Wonsuk Yoo, George Rust, Shun Zhang, James Lillard. Health disparity characteristics on growth patterns of breast cancer mortality trends among the US Counties, 1989-2010. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3701. doi:10.1158/1538-7445.AM2015-3701
Abstract 3703: A prospective study of racial/ethnic disparities in pain experience among breast cancer patients undergoing radiotherapy
Authors: Lee Eunkyung , Takita Cristiane , Wright Jean L. , Reis Isildinha M. , Zhao Wei , Hu Jennifer J. 
Published: August 2015

Abstract
Purpose: Pain is one of the multiple quality of life issues in breast cancer survivors. We sought to determine whether race/ethnic disparity exists in radiotherapy (RT)-induced pain and to assess associated risk factors.
Methods and Materials: Consecutive 375 female patients undergoing adjuvant RT after breast-conserving surgery during 2009-2014 were evaluated. Pain score was assessed as mean of the four pain severity items (pain at its worst, least, average, and now) using 11-point numeric rating scale (0-10) at pre-RT and post-RT. Pain scores of 4 to 10 were regarded as clinically relevant pain. Pain presence and RT-induced change were examined. In multivariable logistic regression analysis, we evaluated risk factors for pre-RT, post-RT, and RT-induced pain.
Results: A total of 15.5% participants self-identified as non-Hispanic white (NHW), 20.8% African American (AA), and 63.7% as Hispanic white (HW). AA patients were more likely to be obese, to report comorbidities, and to have advanced diseases. Pain prevalence was 15.9% at pre-RT and 31.3% at post-RT while 19.7% of patients experienced RT-induced pain. Post-RT pain severity and pain presence were associated with race/ethnicity, age, BMI, number of comorbidity, tumor stage, HER2 status, axillary surgery, fractionation, RT dose, breast volume, and hotspot volume (V105). Multivariable analyses identified HW and obese as independently associated with pre-RT pain while AA, HW, younger age (&lt;50), number of comorbidity (≥2), V105, and pre-RT pain score with post-RT pain. Multivariable analysis also identified AA (OR = 3.23; 95% CI = 1.05-9.93, p = 0.041), younger age (OR = 2.45, 95% CI = 1.24-4.85, p = 0.010), and number of comorbidity (OR = 3.05, 95% CI = 1.29-7.21, p = 0.011 for 2; OR = 4.58, 95% CI = 1.46-14.37, p = 0.009 for at least 3) as risk factors for RT-induced pain.
Conclusions: This prospective study demonstrates AA and younger women are more susceptible to RT-induced pain. In addition, the management of comorbidity conditions, such as diabetes, hypertension, and thyroid disease, deserves attention to prevent RT-induced pain in breast cancer patients.
Citation Format: Eunkyung Lee, Cristiane Takita, Jean L. Wright, Isildinha M. Reis, Wei Zhao, Jennifer J. Hu. A prospective study of racial/ethnic disparities in pain experience among breast cancer patients undergoing radiotherapy. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3703. doi:10.1158/1538-7445.AM2015-3703
Abstract 3709: Second cancers following Waldenström macroglobulinemia/lymphoplasmacytic lymphoma in the United States: analysis of Surveillance, Epidemiology and End Results (SEER) registry data, 1992 - 2011
Authors: McMaster Mary L. , Goldin Lynn R. , Caporaso Neil E. 
Published: August 2015

Abstract
Waldenström macroglobulinemia (WM) is a subtype of lymphoplasmacytic lymphoma (LPL) that features secretion of monoclonal immunoglobulin type M (IgM) in the blood. WM/LPL occurs most commonly in elderly (median, 73 years) white males and is characterized by an indolent course and relatively long survival. Thus, WM/LPL patients may be at risk for development of subsequent cancers. We used data from the National Cancer Institute Surveillance, Epidemiology and End Results (SEER) program to evaluate the risk of subsequent primary cancer in more than 3800 patients diagnosed with WM or LPL during the 20-year period, 1992 - 2011. We calculated observed-to-expected (O/E) standardized incidence ratios, together with 95% confidence intervals (95%CI), for invasive cancers occurring in these individuals. We found that the overall risk for second cancers was significantly increased among survivors of WM/LPL (O/E = 1.49; 95%CI 1.37-1.62) and risk increased with time since diagnosis. Increased risk was observed for both solid tumors (O/E = 1.21; 95%CI 1.09-1.33) and hematolymphoid cancers (O/E = 4.20; 95%CI 3.54-4.95). Significantly increased site-specific risks were seen for cancers of the lung and bronchus, melanoma, non-epithelial skin, and thyroid as well as for Hodgkin and non-Hodgkin lymphoma, multiple myeloma, and acute myeloid leukemia. Sample size limited subset analysis; however, overall increased risk was observed in all race (white, black, Asian/Pacific Islanders) and gender categories except for Asians/Pacific Islanders. Risk for second cancers appeared greater in younger patients (&lt;65 vs. 65+) as well as in those diagnosed more recently, which may reflect changes in treatment regimens over time. We conclude that host factors, shared exposures and treatment effects may play a role in these observations.
Citation Format: Mary L. McMaster, Lynn R. Goldin, Neil E. Caporaso. Second cancers following Waldenström macroglobulinemia/lymphoplasmacytic lymphoma in the United States: analysis of Surveillance, Epidemiology and End Results (SEER) registry data, 1992 - 2011. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3709. doi:10.1158/1538-7445.AM2015-3709
Abstract 3711: The decrease in global cancer mortality
Authors: Boffetta Paolo 
Published: August 2015

Abstract
Background: A decrease in cancer mortality has been reported in the United States, Europe and other developed regions of the world during the last two decades. Whether similar trends apply to less-developed countries - and globally - is unclear.
Methods: We aimed to describe the global patterns of cancer mortality by conducting a systematic analysis of the WHO mortality database for countries for which high- or intermediate-quality data on death certifications are available for a period of at least 10 years (typically 2003-2012). We included 60 countries in the analysis, and calculated age-specific and age-adjusted mortality rates.
Results: A decrease in overall cancer mortality of approximately 1% per year was present in both developed and less-developed regions, and in both genders. For cancers of the esophagus, stomach, larynx and thyroid, the average decrease in global mortality rate was greater than 2% per year. Individual cancers which showed an increase in mortality rates on a global scale are limited to pancreas and brain (both genders), lung (women), melanoma and kidney (men) and endometrium.
Conclusions: Reasons for the decrease in cancer mortality in less-developed countries may include decrease in cancer incidence, shift in the stage distribution, shift in the proportional contribution of individual cancers, and improved therapy. The increase in the number of cancer deaths, globally and in less-developed countries, is primarily driven by changes in the demographic structure of the population, but the risk of the individual of dying from cancer appears to decrease in all countries with reliable data. Cancers with increasing mortality rates should be given priority for research.
Citation Format: Paolo Boffetta. The decrease in global cancer mortality. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3711. doi:10.1158/1538-7445.AM2015-3711
Abstract 3712: Incidence trend of NPC using age-period-cohort analysis from1987 to 2011 in Sihui County, southern China
Authors: Liu Qing , Cao Sumei , Huang Qihong , Zhang Lifang , Li Yanhua , Xie Shanghang 
Published: August 2015

Abstract
In the past several decades, declining incidence rates of NPC have been observed in Chinese populations in Hong Kong, Taiwan, Los Angeles, and Singapore.However, the incidents rates in southern China have remained stable.This study describes the incidence trend of nasopharyngeal carcinoma (NPC) using age-period-cohort (APC) analysis from 1987 to 2011 in Sihui County, southern China. Age-standardized incidence rates compared with the world standard population were examined in both males and females. A Joinpoint regression analysis was conducted to quantify the changes in incidence trends. A Poisson regression APC model was used to assess the age, period, and birth cohort effects on incidence. Age-standardized incidence rates during the study period were 30.29 and 13.09 per 100,000 for males and females, respectively. The incidence rates of NPC remained stable with a non statistical significant average annual percentage change of 0.2% for males and -1.6% for females throughout the entire period. A statistically significant increase (estimated annual percentage change, 6.8%; 95% confidence interval, 0.1%-14.0%) was observed from 2003 to 2009 for males. The incidence of NPC increased with advancing age up to ages 50-59 and decreased at ages &gt;60 years. The curves of NPC incidence by period were virtually flat for males and females. The curve for males by birth cohort showed an increase from the 1922 to 1952 cohort and a decrease thereafter. In females, there was an undulating increase in relative risks from the 1922 to 1972 cohort. In conclusion, the incidence trends for NPC remained generally stable in Sihui from 1987 to 2011, with an increase during 2003-2009. The relative risks of NPC increased in younger female cohorts, the underlying reason of which is expected to be further explored.
Note: This abstract was not presented at the meeting.
Citation Format: Qing Liu, Sumei Cao, Qihong Huang, Lifang Zhang, Yanhua Li, Shanghang Xie. Incidence trend of NPC using age-period-cohort analysis from1987 to 2011 in Sihui County, southern China. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3712. doi:10.1158/1538-7445.AM2015-3712
Abstract 3718: Trends in tobacco use and prostate cancer mortality in four US states, 1999-2010
Authors: Jones Miranda R. , Joshu Corinne E. , Kanarek Norma F. , Navas-Acien Ana , Richardson Kelly A. , Platz Elizabeth A. 
Published: August 2015

Abstract
Background: In the US, prostate cancer mortality rates have declined in past decades. Cigarette smoking, a risk factor for prostate cancer death, has also declined. It is unknown whether declines in smoking prevalence produced detectable declines in prostate cancer mortality in the population.
Objective: To examine prostate cancer mortality rates in relation to changes in tobacco use in the population.
Methods: We studied men ≥35 years of age from California, Kentucky, Maryland and Utah. State smoking prevalences were obtained from the Behavioral Risk Factor Surveillance System (BRFSS). Mortality rates for prostate cancer and external causes, as a control condition, were obtained from the Centers for Disease Control and Prevention's Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) system. The average annual percent change for smoking and prostate cancer mortality for 1999 to 2010 was estimated using joinpoint analysis.
Results: In 1999, the smoking prevalence among men ≥35 years of age was 31.7%, 20.9%, 19.9% and 14.8% in Kentucky, Maryland, California and Utah, respectively. Between 1999 and 2010, smoking in Kentucky declined by 3.0% per year (95% CI: -4.0%, -1.9%) and prostate cancer mortality declined by 3.5% per year (95% CI: -4.3%, -2.7%). In Maryland, smoking declined non-significantly by 3.0% per year (95% CI: -7.0%, 1.2%) and prostate cancer mortality declined by 3.5% per year (95% CI: -4.1%, -3.0%). In California, smoking declined by 3.5% per year (95% CI: -4.4%, -2.5%) and prostate cancer mortality declined by 2.5% per year (95% CI: -2.9%, -2.2%). In Utah, smoking declined by 3.5% per year (95% CI: -5.6%, -1.3%) and prostate cancer mortality declined by 2.1% per year (95% CI: -3.8%, -0.4%). No such patterns were observed for smoking and external causes of death in any of the states.
Conclusion: Similar declines were observed in the prevalence of smoking and prostate cancer mortality. Although ecological, this study suggests that declines in prostate cancer mortality rates are consistent with a beneficial effect of reducing tobacco use at the population level.
Citation Format: Miranda R. Jones, Corinne E. Joshu, Norma F. Kanarek, Ana Navas-Acien, Kelly A. Richardson, Elizabeth A. Platz. Trends in tobacco use and prostate cancer mortality in four US states, 1999-2010. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3718. doi:10.1158/1538-7445.AM2015-3718